Michael P. Samar - 21 Jun 2024 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Reporting relationship: Director
Issuer ticker: UBX
Reported as of: 21 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2024, 16:30:03 UTC
Prior SEC filing: 26 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Alexander Nguyen, Attorney-in-Fact for Michael P. Samar

Key filing fact

Michael P. Samar filed Form 4 for Unity Biotechnology, Inc. (UBX) on 21 Jun 2024.

Key facts

This page summarizes Michael P. Samar's Form 4 filing for Unity Biotechnology, Inc. (UBX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jun 2024, 16:30.

Change

Previous filing in this sequence was filed on 26 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UBX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 21 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $1.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.